Your browser doesn't support javascript.
loading
Retrograde Chronic Total Occlusion Percutaneous Coronary Intervention via Saphenous Vein Graft.
Xenogiannis, Iosif; Gkargkoulas, Fotis; Karmpaliotis, Dimitri; Krestyaninov, Oleg; Khelimskii, Dmitrii; Jaffer, Farouc A; Khatri, Jaikirshan J; Kandzari, David E; Wyman, R Michael; Doing, Anthony H; Dattilo, Phil; Toma, Catalin; Yeh, Robert W; Tamez, Hector; Choi, James W; Jaber, Wissam; Samady, Habib; Sheikh, Abdul M; Potluri, Srinivasa; Patel, Mitul; Mahmud, Ehtisham; Elbaruni, Basem; Love, Michael P; Koutouzis, Michalis; Tsiafoutis, Ioannis; Jefferson, Brian K; Patel, Taral; Uretsky, Barry; Moses, Jeffrey W; Lembo, Nicholas J; Parikh, Manish; Kirtane, Ajay J; Ali, Ziad A; Hall, Allison B; Megaly, Michael S; Vemmou, Evangelia; Nikolakopoulos, Ilias; Rangan, Bavana V; Morley, Pamela W; Bou Dargham, Bassel; Abdullah, Shuaib; Garcia, Santiago; Banerjee, Subhash; Burke, M Nicholas; Brilakis, Emmanouil S; Alaswad, Khaldoon.
Afiliação
  • Xenogiannis I; Minneapolis Heart Institute, Abbott Northwestern Hospital, Minneapolis, Minnesota.
  • Gkargkoulas F; Columbia University, New York, New York.
  • Karmpaliotis D; Columbia University, New York, New York.
  • Krestyaninov O; Meshalkin Novosibirsk Research Institute, Novosibirsk, Russia.
  • Khelimskii D; Meshalkin Novosibirsk Research Institute, Novosibirsk, Russia.
  • Jaffer FA; Massachusetts General Hospital, Boston, Massachusetts.
  • Khatri JJ; Cleveland Clinic, Cleveland, Ohio.
  • Kandzari DE; Piedmont Heart Institute, Atlanta, Georgia.
  • Wyman RM; Torrance Memorial Medical Center, Torrance, California.
  • Doing AH; Medical Center of the Rockies, Loveland, Colorado.
  • Dattilo P; Medical Center of the Rockies, Loveland, Colorado.
  • Toma C; University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
  • Yeh RW; Beth Israel Deaconess Medical Center, Boston, Massachusetts.
  • Tamez H; Beth Israel Deaconess Medical Center, Boston, Massachusetts.
  • Choi JW; Baylor Heart and Vascular Hospital, Dallas, Texas.
  • Jaber W; Emory University Hospital Midtown, Atlanta, Georgia.
  • Samady H; Emory University Hospital Midtown, Atlanta, Georgia.
  • Sheikh AM; Wellstar Health System, Marietta, Georgia.
  • Potluri S; The Heart Hospital Baylor Plano, Plano, Texas.
  • Patel M; VA San Diego Healthcare System and University of California, San Diego, La Jolla, California.
  • Mahmud E; VA San Diego Healthcare System and University of California, San Diego, La Jolla, California.
  • Elbaruni B; St. Boniface General Hospital, Winnipeg, Manitoba, Canada.
  • Love MP; St. Boniface General Hospital, Winnipeg, Manitoba, Canada.
  • Koutouzis M; Red Cross Hospital of Athens, Athens, Greece.
  • Tsiafoutis I; Red Cross Hospital of Athens, Athens, Greece.
  • Jefferson BK; Tristar Centennial Medical Center, Nashville, Tennessee.
  • Patel T; Tristar Centennial Medical Center, Nashville, Tennessee.
  • Uretsky B; VA Central Arkansas Healthcare System, Little Rock, Arkansas.
  • Moses JW; Columbia University, New York, New York.
  • Lembo NJ; Columbia University, New York, New York.
  • Parikh M; Columbia University, New York, New York.
  • Kirtane AJ; Columbia University, New York, New York.
  • Ali ZA; Columbia University, New York, New York.
  • Hall AB; Minneapolis Heart Institute, Abbott Northwestern Hospital, Minneapolis, Minnesota.
  • Megaly MS; Minneapolis Heart Institute, Abbott Northwestern Hospital, Minneapolis, Minnesota.
  • Vemmou E; Minneapolis Heart Institute, Abbott Northwestern Hospital, Minneapolis, Minnesota.
  • Nikolakopoulos I; Minneapolis Heart Institute, Abbott Northwestern Hospital, Minneapolis, Minnesota.
  • Rangan BV; Minneapolis Heart Institute, Abbott Northwestern Hospital, Minneapolis, Minnesota.
  • Morley PW; Minneapolis Heart Institute, Abbott Northwestern Hospital, Minneapolis, Minnesota.
  • Bou Dargham B; VA North Texas Health Care System and University of Texas Southwestern Medical Center, Dallas, Texas.
  • Abdullah S; VA North Texas Health Care System and University of Texas Southwestern Medical Center, Dallas, Texas.
  • Garcia S; Minneapolis Heart Institute, Abbott Northwestern Hospital, Minneapolis, Minnesota.
  • Banerjee S; VA North Texas Health Care System and University of Texas Southwestern Medical Center, Dallas, Texas.
  • Burke MN; Minneapolis Heart Institute, Abbott Northwestern Hospital, Minneapolis, Minnesota.
  • Brilakis ES; Minneapolis Heart Institute, Abbott Northwestern Hospital, Minneapolis, Minnesota. Electronic address: esbrilakis@gmail.com.
  • Alaswad K; Henry Ford Hospital, Detroit, Michigan.
JACC Cardiovasc Interv ; 13(4): 517-526, 2020 02 24.
Article em En | MEDLINE | ID: mdl-32081243
ABSTRACT

OBJECTIVES:

The aim of this study was to examine the use of saphenous vein grafts (SVGs) for retrograde crossing during chronic total occlusion (CTO) percutaneous coronary intervention (PCI).

BACKGROUND:

The use of SVGs for retrograde crossing during CTO PCI has received limited study.

METHODS:

A total of 1,615 retrograde CTO PCIs performed between 2012 and 2019 at 25 centers were examined. Clinical, angiographic, and technical characteristics and procedural outcomes were compared among retrograde cases via SVGs (SVG group) versus other collateral vessels (non-SVG group).

RESULTS:

Retrograde CTO PCI via SVGs was performed in 189 cases (12%). Patients in the SVG group were older (mean age 70 ± 9 years vs. 64 ± 10 years; p < 0.01) and had higher rates of prior myocardial infarction (62% vs. 51%; p < 0.01) and prior PCI (81% vs. 70%; p < 0.01). They were more likely to have moderate or severe calcification (81% vs. 65%; p < 0.01) and moderate or severe tortuosity (53% vs. 44%; p = 0.02) and had similar J-CTO (Multicenter CTO Registry in Japan) scores (3.2 ± 1.0 vs. 3.1 ± 1.1; p = 0.13) but higher PROGRESS-CTO (Prospective Global Registry for the Study of Chronic Total Occlusion Intervention) scores (4.7 ± 1.7 vs. 3.1 ± 1.1; p < 0.01). Technical (85% vs. 78%; p = 0.04) and procedural (81% vs. 74%; p = 0.04) success rates were higher in the SVG group, with no difference in in-hospital major adverse events (6.4% vs. 4.4%; p = 0.22). Contrast volume was lower in the SVG group (225 ml [173 to 325 ml] vs. 292 ml [202 to 400 ml]; p < 0.01).

CONCLUSIONS:

Use of SVGs for retrograde crossing is associated with higher rates of technical and procedural success and similar rates of in-hospital major adverse cardiac events compared with retrograde CTO PCI via other collateral vessels.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Veia Safena / Ponte de Artéria Coronária / Oclusão Coronária / Intervenção Coronária Percutânea Tipo de estudo: Etiology_studies / Observational_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Veia Safena / Ponte de Artéria Coronária / Oclusão Coronária / Intervenção Coronária Percutânea Tipo de estudo: Etiology_studies / Observational_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article